SFL
Regulatory News:
SFL (Paris:FLY):
Rental income: €198.7 million (up 3.1% like-for-like) EPRA earnings: €119.2 million (up 11.8%) Attributable net profit: €589.8 million Portfolio value (excl. transfer costs): €7,158 million (up 9.0%) EPRA NNNAV: €95.9 per share (up 11.1%) |
The financial statements for the year ended 31 December 2019 were approved by the Board of Directors of Société Foncière Lyonnaise on 6 February 2020 at a meeting chaired by Juan José Brugera.
2019 business indicators were particularly robust, with rental income and EPRA earnings at a record high as a direct result of strong lettings performances, an excellent occupancy rate and a further reduction in borrowing costs. Added to this, the period saw further gains in the portfolio's appraisal value and the Company's net asset value.
The auditors have completed their audit of the annual financial information and are in the process of issuing their report.
Consolidated data (€ millions) |
|
|
|
|
2019 |
2018 |
Change |
Rental income |
198.7 |
193.5 |
+2.7% |
Adjusted operating profit* |
172.8 |
162.1 |
+6.6% |
EPRA earnings |
119.2 |
106.7 |
+11.8% |
Attributable net profit |
589.8 |
351.6 |
- |
* Operating profit before disposal gains and losses and fair value adjustments
|
|
|
|
|
31/12/2019 |
31/12/2018 |
Change |
Attributable equity |
4,485 |
4,010 |
+11.9% |
Consolidated portfolio value excluding transfer costs |
7,158 |
6,570 |
+9.0% |
Consolidated portfolio value including transfer costs |
7,632 |
7,005 |
+8.9% |
EPRA NNNAV |
4,461 |
4,017 |
+11.1% |
EPRA NNNAV per share |
€95.9 |
€86.3 |
Results: business indicators at a record high
Rental income:
Rental income amounted to €198.7 million in 2019 versus €193.5 million the previous year, an increase of €5.2 million (2.7%).
- On a like-for-like basis (excluding all changes in the portfolio affecting year-on-year comparisons), rental income was €5.6 million (3.1%) higher. The increase was attributable to new leases signed in 2018 and 2019, mainly in the Cézanne Saint-Honoré, Washington Plaza and Louvre Saint-Honoré properties, and to index increases.
- Rental income from spaces being redeveloped was down by €2.9 million, mainly reflecting the departure of all the tenants from the 83 Marceau building, which is currently being renovated and remarketed, and the refurbishment of several floors in the 176 Charles de Gaulle building in Neuilly that were vacated at the end of 2018.
- Lastly, income from various penalties was up by €2.4 million, mainly due to the early termination of a lease at 103 Grenelle in the third quarter.
Operating profit before disposals and fair value adjustments to investment property amounted to €172.8 million in 2019, an increase of 6.6% from €162.1 million the year before.
Portfolio appraisal value:
The portfolio’s appraisal value grew by 9.0% over the year, despite the absence of any property acquisitions. The increase led to the recognition of positive fair value adjustments to investment property of €526.9 million in 2019 compared with positive adjustments of €289.0 million in 2018.
Net profit:
Net finance costs amounted to €28.1 million in 2019 versus €52.0 million the previous year. The €23.9 million decrease was primarily due to the high basis of comparison created in 2018 by the non‑recurring costs recorded on €300 million worth of bond buybacks. Recurring finance costs, which came to €26.4 million, declined by a significant €4.2 million over the year, reflecting a further improvement in average refinancing costs.
After taking into account these key items, the Group reported attributable net profit for the year of €589.8 million, versus €351.6 million in 2018.
Excluding the impact of disposals, changes in the fair value of investment property and financial instruments and the related tax effect, the Group’s EPRA earnings rose by a strong 11.8% in 2019 to a record high of €119.2 million compared with €106.7 million the previous year.
Operations: SFL continues to enjoy brisk letting activity in a buoyant market, while development projects move ahead at full pace
Rental operations:
In 2019, the office rental market in the Paris region continued to perform very well, supported by strong demand especially for prime properties, a historically low vacancy rate and rising rental values.
In this environment, SFL signed leases on around 56,000 sq.m. in 2019 on very good terms. The main new leases concerned:
- Louvre Saint-Honoré, with the fulfilment of the conditions precedent of the turnkey lease signed with the Cartier Foundation for 20,100 sq.m. GLA of retail space on the lower floors of the building to be delivered in 2023.
- 106 Haussmann, with approximately 12,000 sq.m. pre-let to WeWork.
- 103 Grenelle, with a total of some 5,000 sq.m. let to several different tenants including ADP, Huawei and Wemanity.
- Edouard VII, with around 2,500 sq.m. let to Netflix.
- 176 Charles de Gaulle in Neuilly, with three refurbished floors let to FHB and Manpower.
In addition, new leases were signed with existing tenants such as GIE Carte Bancaire, Facebook, Zurich Insurance and Edouard Denis Développement, on expiry of their previous lease or to meet their changing needs.
Nominal rents for office leases signed in 2019 averaged €754 per sq.m., with effective rents averaging €659 per sq.m. for an average non-cancellable term of 8.1 years, reflecting the previously mentioned good performance of the rental market and the quality of SFL’s buildings.
The physical occupancy rate for revenue-generating properties continued to hold firm, at 97.4% at 31 December 2019 versus 97.3% a year earlier. The EPRA vacancy rate remained at a very low 1.6%. These ratios confirm SFL’s ability to keep its lettable properties fully occupied.
Development operations:
Properties undergoing development at 31 December 2019 represented roughly 18% of the total portfolio. They consist mainly of the Group’s current three flagship projects concerning:
- Retail space in the Louvre Saint-Honoré complex, for which the planning appeal process for the new building permit obtained in March 2019 has now ended, allowing renovation work to begin in first-half 2020. Delivery is scheduled for 2023 under the turnkey lease signed with the Cartier Foundation.
- The Biome office complex on avenue Emile Zola (approximately 24,500 sq.m.), which will be comprehensively remodelled over the next two years. The planning appeal process for the building permit obtained in May 2018 has ended (the permit is now final). The property has been cleared and prepared for renovation and remodelling work has recently begun, with delivery scheduled for late 2021.
- The office building at 83 avenue Marceau (approximately 9,600 sq.m.), which is in the process of being redeveloped with delivery scheduled for the first half of 2021.
Capitalized work carried out in 2019 totalled €49.9 million and concerned the above three redevelopment projects, as well as the full renovation of several floors in the Washington Plaza, 9 Percier and 176 Charles de Gaulle (Neuilly) buildings.
Portfolio operations:
No properties were purchased or sold during 2019.
Financing: historically low debt and average borrowing costs
Several financing transactions were carried out during the year as part of the process of active debt management. The aim of these transactions was to take advantage of the low interest rate environment to further reduce the Company’s average borrowing costs while also extending the average maturity of its fixed rate hedges.
The €390 million five-year syndicated revolving line of credit set up in June has increased the amount and extended the maturity of the Company’s undrawn confirmed lines of credit, which totalled €990 million at 31 December 2019.
The Company also took advantage of the very low interest rates available in the third quarter of 2019 to increase its fixed rate hedges by setting up forward swaps and a collar on a total notional amount of €300 million expiring between September and November 2026.
In addition, maximum issuance under the negotiable European commercial paper (NEU-CP) programme was increased to €500 million. Issuance under the program amounted to €387 million at 31 December 2019.
Net debt at 31 December 2019 amounted to €1,732 million, compared with €1,688 million at 31 December 2018, representing a loan-to-value ratio of 22.7%. The average maturity of net debt was 4.2 years and the average cost after hedging was 1.4%, down from the year-earlier level. At the same date, the interest coverage ratio stood at 6.6x.
EPRA NNNAV up 11.1%
The consolidated market value of the portfolio at 31 December 2019 was €7,158 million excluding transfer costs, an increase of 9.0% from €6,570 million at 31 December 2018. The increase reflected a targeted narrowing of yields on prime Paris properties, a further increase in rental values resulting from the Company’s good lettings performance during the year, and changes in the status of properties undergoing redevelopment in 2019 with the completion of major administrative and marketing phases.
The average EPRA topped-up net initial yield (NIY) was 3.0% at 31 December 2019, down slightly from 3.2% at 31 December 2018.
EPRA NNNAV stood at €4,461 million or €95.9 per share at 31 December 2019, an increase of 11.1% versus €86.3 per share at 31 December 2018 (after payment of a dividend of €2.65 per share in April 2019).
Dividend
At the Annual General Meeting to be held on 3 April 2020, the Board of Directors will recommend paying a dividend of €2.65 per share.
EPRA indicators
2019 |
2018 |
|
EPRA Earnings (€m) |
119.2 |
106.7 |
/share |
€2.56 |
€2.29 |
EPRA Cost Ratio (including vacancy costs) |
13.3% |
13.9% |
EPRA Cost Ratio (excluding vacancy costs) |
12.4% |
12.6% |
31/12/2019 |
31/12/2018 |
|
EPRA NAV (€m) |
4,623 |
4,142 |
/share |
€99.4 |
€89.0 |
EPRA NNNAV (€m) |
4,461 |
4,017 |
/share |
€95.9 |
€86.3 |
EPRA Net Initial Yield (NIY) |
2.7% |
2.8% |
EPRA topped-up NIY |
3.0% |
3.2% |
EPRA Vacancy Rate |
1.6% |
1.6% |
Alternative Performance Indicators (APIs)
API EPRA earnings
€ millions |
2019 |
2018 |
Attributable net profit |
589.8 |
351.6 |
Less: |
|
|
Profit (loss) on asset disposals |
- |
- |
Fair value adjustments to investment property |
(526.9) |
(289.0) |
Fair value adjustments to financial instruments, discounting adjustments to debt and related costs |
1.7 |
21.4 |
Tax on the above items |
14.0 |
5.3 |
Non-controlling interests in the above items |
40.6 |
17.3 |
EPRA earnings |
119.2 |
106.7 |
API EPRA NNNAV
€ millions |
31/12/2019 |
31/12/2018 |
Attributable equity |
4,485 |
4,010 |
Treasury shares |
8 |
10 |
Unrealised capital gains |
23 |
19 |
Fair value adjustments to fixed rate debt |
(55) |
(22) |
EPRA NNNAV |
4,461 |
4,017 |
API net debt
€ millions |
31/12/2019 |
31/12/2018 |
Long-term borrowings and derivative instruments |
1,441 |
1,494 |
Short-term borrowings and other interest-bearing debt |
393 |
269 |
Debt in the consolidated statement of financial position |
1,834 |
1,763 |
Less: |
|
|
Current account advances (liabilities) |
(50) |
(52) |
Accrued interest, deferred recognition of debt arranging fees, negative fair value adjustments to financial instruments |
1 |
2 |
Cash and cash equivalents |
(54) |
(25) |
Net debt |
1,732 |
1,688 |
More information is available at www.fonciere-lyonnaise.com
About SFL
Leader in the prime segment of the Parisian commercial real estate market, Société Foncière Lyonnaise stands out for the quality of its property portfolio, which is valued at €7.2 billion and is focused on the Central Business District of Paris (#cloud.paris, Edouard VII, Washington Plaza, etc.), and for the quality of its client portfolio, which is composed of prestigious companies in the consulting, media, digital, luxury, finance and insurance sectors. As France’s oldest property company, SFL demonstrates year after year an unwavering commitment to its strategy focused on creating a high value in use for users and, ultimately, substantial appraisal values for its properties.
Stock market: Euronext Paris Compartment A – Euronext Paris ISIN FR0000033409 – Bloomberg: FLY FP – Reuters: FLYP PA
S&P rating: BBB+ stable outlook
View source version on businesswire.com: https://www.businesswire.com/news/home/20200206005806/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
